Department of Obstetrics & Gynaecology, Singapore General Hospital, Singapore.
Ann Acad Med Singap. 2017 Jul;46(7):267-273.
This study aimed to determine the prevalence of cervical intraepithelial neoplasia grade 3 or worse (≥CIN3) and cost-effectiveness of human papillomavirus (HPV) genotyping with reflex liquid-based cytology (LBC) for cervical cancer screening in Singapore.
Women who were ≥25 years old and undertook co-testing with LBC and HPV-genotyping (Cobas-4800, Roche, USA) for HPV-16, HPV-18 and 12 high-risk HPV types in a single institution were studied retrospectively. A single cervical smear in ThinPrep® PreservCyt® solution (Hologic, USA) was separated for tests in independent cytology and molecular pathology laboratories. The results were reviewed by a designated gynaecologist according to institutional clinical management protocols. Those who tested positive for HPV-16 and/or HPV-18 (regardless of cytology results), cytology showing low-grade squamous intraepithelial lesions (LSIL) or high-grade SIL (HSIL), or atypical squamous cells of undetermined significance (ASCUS) with positive 12 high-risk HPV types were referred for colposcopy. Colposcopy was performed by experienced colposcopists. Cervical biopsy, either directed punch biopsies or excisional biopsy, was determined by a colposcopist. The diagnosis of ≥CIN3 was reviewed by a gynaecologic pathologist. Cost-effectiveness of HPV-based screening in terms of disease and financial burden was analysed using epidemiological, clinical and financial input data from Singapore.
Of 1866 women studied, 167 (8.9%) had abnormal cytology (≥ASCUS) and 171 (9.2%) tested positive for high-risk HPV. Twenty-three CIN were detected. Three of the 10 ≥CIN3 cases had negative cytology but positive HPV-16. Compared to cytology, HPV genotyping detected more ≥CIN3 (OR: 1.43). HPV+16/18 genotyping with reflex LBC was superior in terms of cost-effectiveness to LBC with reflex HPV, both for disease detection rate and cost per case of ≥CIN2 detected.
Compared to cytology, HPV+16/18 genotyping with reflex LBC detected more ≥CIN3 and was cost-effective for cervical screening in Singapore.
本研究旨在确定新加坡人乳头瘤病毒(HPV)基因分型与液基细胞学(LBC)联合筛查宫颈癌时,宫颈上皮内瘤变 3 级或更高级别(≥CIN3)的患病率和成本效益。
回顾性分析在单家机构中,≥25 岁且接受 LBC 和 HPV 基因分型(罗氏公司的 Cobas-4800,美国)联合检测 HPV-16、HPV-18 和 12 种高危 HPV 型的女性。单个宫颈液基薄层细胞学检查(美国豪洛捷公司的 ThinPrep® PreservCyt® 溶液)标本被分为独立的细胞学和分子病理学实验室进行检测。根据机构临床管理方案,由指定的妇科医生对结果进行审查。HPV-16 和/或 HPV-18(无论细胞学结果如何)阳性、细胞学显示低级别鳞状上皮内病变(LSIL)或高级别 SIL(HSIL)、或不典型鳞状细胞意义不明确(ASCUS)且 12 种高危 HPV 型阳性的患者,转诊行阴道镜检查。阴道镜检查由经验丰富的阴道镜医生进行。阴道镜医生决定行宫颈活检,包括直接活检或切除术。≥CIN3 的诊断由妇科病理学家进行审查。基于疾病和经济负担,利用新加坡的流行病学、临床和财务投入数据,对 HPV 筛查的成本效益进行分析。
在 1866 名研究女性中,167 名(8.9%)有异常细胞学(≥ASCUS),171 名(9.2%)HPV 高危型阳性。发现 23 例 CIN。10 例≥CIN3 病例中有 3 例细胞学阴性但 HPV-16 阳性。与细胞学相比,HPV 基因分型检测到更多的≥CIN3(OR:1.43)。HPV+16/18 基因分型联合 LBC 比 LBC 联合 HPV 基因分型在疾病检出率和每例≥CIN2 检出的成本效益方面更具优势。
与细胞学相比,HPV+16/18 基因分型联合 LBC 检测出更多的≥CIN3,在新加坡进行宫颈癌筛查时具有成本效益。